A phase 1 trial of the histone deacetylase inhibitor AR-42 in patients with neurofibromatosis type 2-associated tumors and advanced solid malignancies
ConclusionSingle-agent AR-42 is safe and well tolerated. Further studies may consider AR-42 in a larger cohort of patients with NF2 or in combination with other agents in advanced solid tumors.Trial registrationNCT01129193, registered 5/24/2010.
Source: Cancer Chemotherapy and Pharmacology - Category: Cancer & Oncology Source Type: research
More News: Brain | Breast Cancer | Breast Carcinoma | Cancer | Cancer & Oncology | Carcinoma | Carcinoma of Unknown Primary | Chemotherapy | Drugs & Pharmacology | Eye Cancers | Hematology | Lung Cancer | Melanoma | Men | Neurofibromatosis | Neurology | Oral Cancer | Sertoli Cell Tumor | Skin Cancer | Study | Thrombocytopenia | Toxicology | Uveal Melanoma